Trial Profile
A Phase 1, Randomized, Double-Blind, Placebo-controlled Study to Evaluate the Effect of Ozanimod on Blood Pressure and Heart Rate Response to Pseudoephedrine in Healthy Adult Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Ozanimod (Primary) ; Pseudoephedrine (Primary)
- Indications COVID 2019 infections; Crohn's disease; Multiple sclerosis; Ulcerative colitis
- Focus Therapeutic Use
- Sponsors Celgene Corporation
- 06 Oct 2020 Results assessing multiple dose pharmacokinetics of ozanimod and its major active metabolites and the pharmacodynamic and pharmacokinetic interactions with pseudoephedrine, a sympathomimetic agent, in healthy subjects, published in the Advances in Therapy
- 28 May 2019 Status changed from recruiting to completed.
- 30 Aug 2018 New trial record